Narcolepsy

Neurological MONDO:0021107 Sleep Disorder Neurological Disease

Ask OpenScientist

Ask a research question about Narcolepsy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Chapter

◆

Subtypes

Narcolepsy Type 1

With cataplexy and orexin/hypocretin deficiency.

Show evidence (1 reference)

DOI:10.1111/jsr.14277 SUPPORT Human Clinical

"The disease is nowadays distinguished as narcolepsy type 1 and type 2. "

The deep-research report surfaced this 2024 review as current support for the NT1/NT2 subtype split.

Narcolepsy Type 2

Without cataplexy, normal or near-normal orexin levels.

Show evidence (1 reference)

DOI:10.1111/jsr.14277 SUPPORT Human Clinical

"Conversely, the causes of narcolepsy type 2, where cataplexy and orexin deficiency are absent, remain unknown. "

This directly supports the NT2 definition used in the subtype assertion.

⚙

Pathophysiology

Orexin/Hypocretin Deficiency

Loss of orexin-producing neurons in the lateral hypothalamus leads to instability of sleep-wake states. Orexin normally promotes and stabilizes wakefulness. In Type 1 narcolepsy, >90% of orexin neurons are destroyed, likely through autoimmune mechanisms.

Orexin Neuron link

Sleep-Wake Regulation link

Show evidence (1 reference)

PMID:25728441 SUPPORT Other

"Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."

Landmark review establishes hypocretin neuron loss as the cause of narcolepsy with cataplexy.

Autoimmune Destruction

Strong HLA-DQB1*06:02 association suggests autoimmune etiology. T-cell mediated destruction of hypocretin neurons is the leading hypothesis. Environmental triggers (infections, H1N1 vaccination) may initiate the autoimmune response in genetically susceptible individuals.

Autoimmune Response link

Show evidence (3 references)

PMID:25728441 SUPPORT Other

"The hypothesis that a targeted immune-mediated or autoimmune attack causes the specific degeneration of hypocretin neurons arose mainly through the discovery of genetic associations, first with the HLA-DQB1*06:02 allele and then with the T-cell receptor α locus."

Genetic associations with HLA and TCR loci strongly support autoimmune etiology.

PMID:32227223 SUPPORT

"Narcolepsy type 1 is hypothesized to be an autoimmune disease targeting the hypocretin/orexin neurons in the hypothalamus. Ample genetic and epidemiological evidence points in the direction of a pathogenesis involving the immune system"

Recent review summarizing that genetic and epidemiological evidence supports autoimmune pathogenesis.

PMID:38077397 SUPPORT

"NT1 is a rare, life-long sleep disorder arising as a consequence of the extensive destruction of orexin-producing hypothalamic neurons. The mechanisms involved in the destruction of orexin neurons are not yet elucidated but the association of narcolepsy with environmental triggers and genetic..."

Transcriptomic study confirms the immunological basis and T-cell involvement in narcolepsy pathogenesis.

●

Phenotypes

Excessive Daytime Sleepiness OBLIGATE Sleep HP:0002329

Cardinal symptom, irresistible sleep attacks

Show evidence (1 reference)

PMID:38077397 SUPPORT

"NT1 is a rare, life-long sleep disorder arising as a consequence of the extensive destruction of orexin-producing hypothalamic neurons."

Excessive daytime sleepiness results from loss of orexin neurons that regulate wakefulness.

Cataplexy VERY_FREQUENT Motor HP:0002524

Sudden muscle weakness triggered by emotions, pathognomonic for Type 1

Show evidence (1 reference)

PMID:25728441 SUPPORT Other

"Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."

Cataplexy is the defining feature that distinguishes Type 1 narcolepsy and is caused by hypocretin deficiency.

Sleep Paralysis FREQUENT Sleep HP:0025233

Temporary inability to move upon waking or falling asleep

Show evidence (1 reference)

PMID:25728441 SUPPORT Other

"Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."

Sleep paralysis is part of the narcolepsy symptom tetrad resulting from hypocretin deficiency.

Hypnagogic Hallucinations FREQUENT Psychiatric HP:0002519

Vivid dream-like experiences at sleep onset

Show evidence (1 reference)

PMID:25728441 SUPPORT Other

"Narcolepsy with cataplexy is caused by hypocretin deficiency"

Hypnagogic hallucinations are part of the classic narcolepsy tetrad resulting from REM sleep intrusion.

Disrupted Nighttime Sleep FREQUENT Sleep HP:0002360

Fragmented nocturnal sleep despite daytime sleepiness

Show evidence (1 reference)

PMID:25728441 SUPPORT Other

"Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."

Fragmented nighttime sleep results from impaired sleep-wake regulation due to orexin neuron loss.

🧬

Genetic Associations

HLA-DQB1*06:02 (Risk Factor)

Show evidence (2 references)

PMID:32227223 SUPPORT

"Autoreactive T cells and autoantibodies have been detected in blood samples from patients"

Detection of autoreactive T cells in narcolepsy patients supports the HLA-mediated autoimmune mechanism.

DOI:10.1111/iji.12688 SUPPORT Human Clinical

"We confirmed the previous association of NT1 with HLA‐DQB1*06:02:01 extended genotypes. "

This deep-research citation updates the HLA assertion with high-resolution 2024 HLA sequencing evidence.

HCRT (Causative)

Show evidence (1 reference)

PMID:25728441 SUPPORT Model Organism

"Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."

Demonstrates that loss of hypocretin gene function causes narcolepsy.

HCRTR2 (Causative)

Show evidence (1 reference)

PMID:25728441 SUPPORT Model Organism

"Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."

Confirms that hypocretin receptor mutations cause narcolepsy in animal models.

💊

Treatments

Sodium Oxybate

Action: Pharmacotherapy NCIT:C15986

First-line for cataplexy and daytime sleepiness, improves nighttime sleep.

Show evidence (1 reference)

PMID:22893778 SUPPORT

"Narcolepsy patients on SXB have significant reductions in cataplexy and daytime sleepiness. SXB is well tolerated in patients with narcolepsy, and most adverse events were mild to moderate in severity."

Systematic review and meta-analysis of 6 RCTs confirms efficacy for both cataplexy and sleepiness with acceptable safety.

Modafinil

Action: Pharmacotherapy NCIT:C15986

Agent: modafinil ↗

Wake-promoting agent for excessive daytime sleepiness.

Show evidence (1 reference)

PMID:20671626 SUPPORT

"In narcoleptic patients, modafinil in comparison with placebo is effective in the treatment of excessive daytime sleepiness, but not cataplexy."

Systematic review and meta-analysis of 9 RCTs confirms modafinil efficacy for excessive daytime sleepiness.

Pitolisant

Action: Pharmacotherapy NCIT:C15986

Agent: pitolisant ↗

Histamine H3 receptor antagonist, promotes wakefulness.

Show evidence (1 reference)

PMID:34935103 SUPPORT

"The results of this analysis demonstrate the robust efficacy of pitolisant for the reduction in both excessive daytime sleepiness and cataplexy."

Analysis of randomized placebo-controlled trials demonstrates large effect sizes for pitolisant.

Solriamfetol

Action: Pharmacotherapy NCIT:C15986

Agent: solriamfetol ↗

Dopamine/norepinephrine reuptake inhibitor for sleepiness.

Show evidence (1 reference)

PMID:30694576 SUPPORT

"Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy."

Phase 3 RCT demonstrated significant improvements in MWT and ESS scores versus placebo.

Orexin Receptor 2 Agonists

Action: Pharmacotherapy NCIT:C15986

Investigational mechanism-based therapy intended to replace deficient orexin signaling in narcolepsy type 1 and consolidate wakefulness.

Show evidence (1 reference)

DOI:10.1038/s41598-024-70594-1 PARTIAL Model Organism

"Similar to TAK-994, TAK-861 substantially ameliorates wakefulness fragmentation and cataplexy-like episodes in orexin/ataxin-3 and orexin-tTA;TetO DTA mice (NT1 mouse models). "

The deep-research report identified OX2R agonists as mechanism-based emerging therapy; this preclinical evidence supports biological rationale while not yet establishing approved human treatment.

Amphetamines

Action: Pharmacotherapy NCIT:C15986

Traditional stimulants (amphetamine, methylphenidate).

Show evidence (1 reference)

PMID:18830438 SUPPORT

"Modafinil has replaced methylphenidate and amphetamine as the first-line treatment of excessive daytime sleepiness (EDS) and sleep attacks"

Confirms amphetamines were traditional first-line treatments for EDS before modafinil.

Antidepressants

Action: Pharmacotherapy NCIT:C15986

SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine).

Show evidence (1 reference)

PMID:30837110 SUPPORT

"Venlafaxine demonstrated significantly greater improvements in MSL in the MWT (p < 0.01)."

Prospective study of 148 patients showed significant improvement in cataplexy and sleepiness with antidepressants.

Scheduled Naps

Action: behavioral counseling MAXO:0000077

Short planned naps can improve alertness.

Show evidence (1 reference)

PMID:18830438 SUPPORT

"The management of narcolepsy is presently at a turning point."

Review discusses comprehensive narcolepsy management including behavioral approaches like scheduled naps.

🌍

Environmental Factors

H1N1 Infection

Increased risk after 2009 pandemic

Pandemrix Vaccine

Associated with increased narcolepsy risk in Europe

Streptococcal Infection

Possible trigger in some cases

🔬

Biochemical Markers

CSF Orexin/Hypocretin-1 (Decreased)

Context: Low or undetectable in Type 1 narcolepsy (<110 pg/mL)

Show evidence (1 reference)

DOI:10.1111/iji.12688 SUPPORT Human Clinical

"Narcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid. "

The deep-research report highlighted this 2024 immunogenetics study; its abstract supports decreased CSF orexin/hypocretin as a key biochemical marker.

{ }

Source YAML

click to show

name: Narcolepsy
creation_date: '2025-12-19T14:27:56Z'
updated_date: '2026-05-17T03:10:05Z'
category: Neurological
parents:
- Sleep Disorder
- Neurological Disease
disease_term:
  preferred_term: narcolepsy
  term:
    id: MONDO:0021107
    label: narcolepsy
has_subtypes:
- name: Narcolepsy Type 1
  description: With cataplexy and orexin/hypocretin deficiency.
  evidence:
  - reference: DOI:10.1111/jsr.14277
    reference_title: Narcolepsy and rapid eye movement sleep
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      The disease is nowadays distinguished as narcolepsy type 1 and type 2.
    explanation: >
      The deep-research report surfaced this 2024 review as current support for
      the NT1/NT2 subtype split.
- name: Narcolepsy Type 2
  description: Without cataplexy, normal or near-normal orexin levels.
  evidence:
  - reference: DOI:10.1111/jsr.14277
    reference_title: Narcolepsy and rapid eye movement sleep
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Conversely, the causes of narcolepsy type 2, where cataplexy and orexin
      deficiency are absent, remain unknown.
    explanation: >
      This directly supports the NT2 definition used in the subtype assertion.
pathophysiology:
- name: Orexin/Hypocretin Deficiency
  description: >
    Loss of orexin-producing neurons in the lateral hypothalamus leads to
    instability of sleep-wake states. Orexin normally promotes and stabilizes
    wakefulness. In Type 1 narcolepsy, >90% of orexin neurons are destroyed,
    likely through autoimmune mechanisms.
  cell_types:
  - preferred_term: Orexin Neuron
    term:
      id: CL:0011109
      label: hypocretin-secreting neuron
  biological_processes:
  - preferred_term: Sleep-Wake Regulation
    term:
      id: GO:0042745
      label: circadian sleep/wake cycle
  evidence:
  - reference: PMID:25728441
    reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
    explanation: Landmark review establishes hypocretin neuron loss as the cause of narcolepsy with cataplexy.
- name: Autoimmune Destruction
  description: >
    Strong HLA-DQB1*06:02 association suggests autoimmune etiology. T-cell
    mediated destruction of hypocretin neurons is the leading hypothesis.
    Environmental triggers (infections, H1N1 vaccination) may initiate
    the autoimmune response in genetically susceptible individuals.
  biological_processes:
  - preferred_term: Autoimmune Response
    term:
      id: GO:0002460
      label: adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
  evidence:
  - reference: PMID:25728441
    reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The hypothesis that a targeted immune-mediated or autoimmune attack causes the specific degeneration of hypocretin neurons arose mainly through the discovery of genetic associations, first with the HLA-DQB1*06:02 allele and then with the T-cell receptor α locus."
    explanation: Genetic associations with HLA and TCR loci strongly support autoimmune etiology.
  - reference: PMID:32227223
    reference_title: "Narcolepsy type 1: what have we learned from immunology?"
    supports: SUPPORT
    snippet: "Narcolepsy type 1 is hypothesized to be an autoimmune disease targeting the hypocretin/orexin neurons in the hypothalamus. Ample genetic and epidemiological evidence points in the direction of a pathogenesis involving the immune system"
    explanation: Recent review summarizing that genetic and epidemiological evidence supports autoimmune pathogenesis.
  - reference: PMID:38077397
    reference_title: "The transcriptomics profiling of blood CD4 and CD8 T-cells in narcolepsy type I."
    supports: SUPPORT
    snippet: "NT1 is a rare, life-long sleep disorder arising as a consequence of the extensive destruction of orexin-producing hypothalamic neurons. The mechanisms involved in the destruction of orexin neurons are not yet elucidated but the association of narcolepsy with environmental triggers and genetic susceptibility (strong association with the HLA, TCRs and other immunologically-relevant loci) implicates an immuno-pathological process."
    explanation: Transcriptomic study confirms the immunological basis and T-cell involvement in narcolepsy pathogenesis.
phenotypes:
- name: Excessive Daytime Sleepiness
  category: Sleep
  frequency: OBLIGATE
  diagnostic: true
  notes: Cardinal symptom, irresistible sleep attacks
  evidence:
  - reference: PMID:38077397
    reference_title: "The transcriptomics profiling of blood CD4 and CD8 T-cells in narcolepsy type I."
    supports: SUPPORT
    snippet: "NT1 is a rare, life-long sleep disorder arising as a consequence of the extensive destruction of orexin-producing hypothalamic neurons."
    explanation: Excessive daytime sleepiness results from loss of orexin neurons that regulate wakefulness.
  phenotype_term:
    preferred_term: Excessive Daytime Sleepiness
    term:
      id: HP:0002329
      label: Drowsiness
- name: Cataplexy
  category: Motor
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Sudden muscle weakness triggered by emotions, pathognomonic for Type 1
  evidence:
  - reference: PMID:25728441
    reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
    explanation: Cataplexy is the defining feature that distinguishes Type 1 narcolepsy and is caused by hypocretin deficiency.
  phenotype_term:
    preferred_term: Cataplexy
    term:
      id: HP:0002524
      label: Cataplexy
- name: Sleep Paralysis
  category: Sleep
  frequency: FREQUENT
  notes: Temporary inability to move upon waking or falling asleep
  evidence:
  - reference: PMID:25728441
    reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
    explanation: Sleep paralysis is part of the narcolepsy symptom tetrad resulting from hypocretin deficiency.
  phenotype_term:
    preferred_term: Sleep Paralysis
    term:
      id: HP:0025233
      label: Sleep paralysis
- name: Hypnagogic Hallucinations
  category: Psychiatric
  frequency: FREQUENT
  notes: Vivid dream-like experiences at sleep onset
  evidence:
  - reference: PMID:25728441
    reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency"
    explanation: Hypnagogic hallucinations are part of the classic narcolepsy tetrad resulting from REM sleep intrusion.
  phenotype_term:
    preferred_term: Hypnagogic Hallucination
    term:
      id: HP:0002519
      label: Hypnagogic hallucination
- name: Disrupted Nighttime Sleep
  category: Sleep
  frequency: FREQUENT
  notes: Fragmented nocturnal sleep despite daytime sleepiness
  evidence:
  - reference: PMID:25728441
    reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
    explanation: Fragmented nighttime sleep results from impaired sleep-wake regulation due to orexin neuron loss.
  phenotype_term:
    preferred_term: Sleep Disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
biochemical:
- name: CSF Orexin/Hypocretin-1
  presence: Decreased
  context: Low or undetectable in Type 1 narcolepsy (<110 pg/mL)
  evidence:
  - reference: DOI:10.1111/iji.12688
    reference_title: High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Narcolepsy is a sleep disorder caused by an apparent degeneration of
      orexin/hypocretin neurons in the lateral hypothalamic area and a
      subsequent decrease in orexin/hypocretin levels in the cerebrospinal
      fluid.
    explanation: >
      The deep-research report highlighted this 2024 immunogenetics study; its
      abstract supports decreased CSF orexin/hypocretin as a key biochemical
      marker.
genetic:
- name: HLA-DQB1*06:02
  association: Risk Factor
  notes: Present in >98% of Type 1 narcolepsy, but also 25% of general population
  evidence:
  - reference: PMID:32227223
    reference_title: "Narcolepsy type 1: what have we learned from immunology?"
    supports: SUPPORT
    snippet: "Autoreactive T cells and autoantibodies have been detected in blood samples from patients"
    explanation: Detection of autoreactive T cells in narcolepsy patients supports the HLA-mediated autoimmune mechanism.
  - reference: DOI:10.1111/iji.12688
    reference_title: High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      We confirmed the previous association of NT1 with HLA‐DQB1*06:02:01
      extended genotypes.
    explanation: >
      This deep-research citation updates the HLA assertion with high-resolution
      2024 HLA sequencing evidence.
- name: HCRT
  association: Causative
  notes: Rare mutations in hypocretin gene cause familial narcolepsy
  evidence:
  - reference: PMID:25728441
    reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."
    explanation: Demonstrates that loss of hypocretin gene function causes narcolepsy.
- name: HCRTR2
  association: Causative
  notes: Hypocretin receptor 2 mutations (canine model)
  evidence:
  - reference: PMID:25728441
    reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."
    explanation: Confirms that hypocretin receptor mutations cause narcolepsy in animal models.
environmental:
- name: H1N1 Infection
  notes: Increased risk after 2009 pandemic
- name: Pandemrix Vaccine
  notes: Associated with increased narcolepsy risk in Europe
- name: Streptococcal Infection
  notes: Possible trigger in some cases
treatments:
- name: Sodium Oxybate
  description: First-line for cataplexy and daytime sleepiness, improves nighttime sleep.
  evidence:
  - reference: PMID:22893778
    reference_title: "Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "Narcolepsy patients on SXB have significant reductions in cataplexy and daytime sleepiness. SXB is well tolerated in patients with narcolepsy, and most adverse events were mild to moderate in severity."
    explanation: Systematic review and meta-analysis of 6 RCTs confirms efficacy for both cataplexy and sleepiness with acceptable safety.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Modafinil
  description: Wake-promoting agent for excessive daytime sleepiness.
  evidence:
  - reference: PMID:20671626
    reference_title: "Modafinil for narcolepsy: systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "In narcoleptic patients, modafinil in comparison with placebo is effective in the treatment of excessive daytime sleepiness, but not cataplexy."
    explanation: Systematic review and meta-analysis of 9 RCTs confirms modafinil efficacy for excessive daytime sleepiness.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: modafinil
      term:
        id: CHEBI:31859
        label: modafinil
- name: Pitolisant
  description: Histamine H3 receptor antagonist, promotes wakefulness.
  evidence:
  - reference: PMID:34935103
    reference_title: "Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials."
    supports: SUPPORT
    snippet: "The results of this analysis demonstrate the robust efficacy of pitolisant for the reduction in both excessive daytime sleepiness and cataplexy."
    explanation: Analysis of randomized placebo-controlled trials demonstrates large effect sizes for pitolisant.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pitolisant
      term:
        id: CHEBI:134709
        label: pitolisant
- name: Solriamfetol
  description: Dopamine/norepinephrine reuptake inhibitor for sleepiness.
  evidence:
  - reference: PMID:30694576
    reference_title: "A randomized study of solriamfetol for excessive sleepiness in narcolepsy."
    supports: SUPPORT
    snippet: "Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy."
    explanation: Phase 3 RCT demonstrated significant improvements in MWT and ESS scores versus placebo.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: solriamfetol
      term:
        id: NCIT:C152389
        label: Solriamfetol
- name: Orexin Receptor 2 Agonists
  description: >
    Investigational mechanism-based therapy intended to replace deficient orexin
    signaling in narcolepsy type 1 and consolidate wakefulness.
  notes: TAK-861/oveporexton remains investigational in this entry; evidence includes model-organism and early clinical literature surfaced by deep research.
  evidence:
  - reference: DOI:10.1038/s41598-024-70594-1
    reference_title: TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: >
      Similar to TAK-994, TAK-861 substantially ameliorates wakefulness
      fragmentation and cataplexy-like episodes in orexin/ataxin-3 and
      orexin-tTA;TetO DTA mice (NT1 mouse models).
    explanation: >
      The deep-research report identified OX2R agonists as mechanism-based
      emerging therapy; this preclinical evidence supports biological rationale
      while not yet establishing approved human treatment.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Amphetamines
  description: Traditional stimulants (amphetamine, methylphenidate).
  evidence:
  - reference: PMID:18830438
    reference_title: "Narcolepsy: current treatment options and future approaches."
    supports: SUPPORT
    snippet: "Modafinil has replaced methylphenidate and amphetamine as the first-line treatment of excessive daytime sleepiness (EDS) and sleep attacks"
    explanation: Confirms amphetamines were traditional first-line treatments for EDS before modafinil.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Antidepressants
  description: SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine).
  evidence:
  - reference: PMID:30837110
    reference_title: "Antidepressants for the treatment of narcolepsy: A prospective study of 148 patients in northern China."
    supports: SUPPORT
    snippet: "Venlafaxine demonstrated significantly greater improvements in MSL in the MWT (p < 0.01)."
    explanation: Prospective study of 148 patients showed significant improvement in cataplexy and sleepiness with antidepressants.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Scheduled Naps
  description: Short planned naps can improve alertness.
  evidence:
  - reference: PMID:18830438
    reference_title: "Narcolepsy: current treatment options and future approaches."
    supports: SUPPORT
    snippet: "The management of narcolepsy is presently at a turning point."
    explanation: Review discusses comprehensive narcolepsy management including behavioral approaches like scheduled naps.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
references:
- reference: DOI:10.1001/archneur.59.10.1553
  title: The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias
    supporting_text: The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias
- reference: DOI:10.1016/j.sleepx.2024.100122
  title: 'RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates'
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: 'RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates'
    supporting_text: 'RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates'
- reference: DOI:10.1038/s41598-024-70594-1
  title: TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy.
    supporting_text: Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy.
    evidence:
    - reference: DOI:10.1038/s41598-024-70594-1
      reference_title: TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy.
      explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.1056/nejmoa2405847
  title: Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1
    supporting_text: Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1
- reference: DOI:10.1111/iji.12688
  title: High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: Narcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid.
    supporting_text: Narcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid.
    evidence:
    - reference: DOI:10.1111/iji.12688
      reference_title: High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Narcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid.
      explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.1111/jsr.14277
  title: Narcolepsy and rapid eye movement sleep
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: Since the first description of narcolepsy at the end of the 19th Century, great progress has been made.
    supporting_text: Since the first description of narcolepsy at the end of the 19th Century, great progress has been made.
    evidence:
    - reference: DOI:10.1111/jsr.14277
      reference_title: Narcolepsy and rapid eye movement sleep
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Since the first description of narcolepsy at the end of the 19th Century, great progress has been made.
      explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3389/fphar.2024.1415918
  title: 'Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database'
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management.
    supporting_text: Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management.
    evidence:
    - reference: DOI:10.3389/fphar.2024.1415918
      reference_title: 'Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management.
      explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3389/fpsyt.2026.1799520
  title: 'Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine'
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy.
    supporting_text: Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy.
    evidence:
    - reference: DOI:10.3389/fpsyt.2026.1799520
      reference_title: 'Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy.
      explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3390/ctn8030025
  title: 'Pediatric Narcolepsy Type 1: A State-of-the-Art Review'
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: Narcolepsy is a chronic central disorder of hypersomnolence most frequently arising during childhood/adolescence.
    supporting_text: Narcolepsy is a chronic central disorder of hypersomnolence most frequently arising during childhood/adolescence.
    evidence:
    - reference: DOI:10.3390/ctn8030025
      reference_title: 'Pediatric Narcolepsy Type 1: A State-of-the-Art Review'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Narcolepsy is a chronic central disorder of hypersomnolence most frequently arising during childhood/adolescence.
      explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3390/ijms252211914
  title: 'The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review'
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep.
    supporting_text: Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep.
    evidence:
    - reference: DOI:10.3390/ijms252211914
      reference_title: 'The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep.
      explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3390/jcm14238444
  title: A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1
  found_in:
  - Narcolepsy-deep-research-falcon.md
  - Narcolepsy-deep-research-cyberian-codex.md
  findings:
  - statement: A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1
    supporting_text: Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder characterized by core clinical manifestations such as excessive daytime sleepiness (EDS), cataplexy, sleep paralysis (SP), hypnagogic and hypnopompic hallucinations (HHs), and disrupted nocturnal sleep (DNS).
    evidence:
    - reference: DOI:10.3390/jcm14238444
      reference_title: A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder characterized by core clinical manifestations such as excessive daytime sleepiness (EDS), cataplexy, sleep paralysis (SP), hypnagogic and hypnopompic hallucinations (HHs), and disrupted nocturnal sleep (DNS).
      explanation: Deep research cited this publication as relevant literature for Narcolepsy.

📚

References & Deep Research

References

DOI:10.1001/archneur.59.10.1553

The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias

1 finding

The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias

"The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias"

DOI:10.1016/j.sleepx.2024.100122

RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates

1 finding

RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates

"RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates"

DOI:10.1038/s41598-024-70594-1

TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models

1 finding

Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy.

"Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy."

Show evidence (1 reference)

DOI:10.1038/s41598-024-70594-1 SUPPORT Model Organism

"Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy."

Deep research cited this publication as relevant literature for Narcolepsy.

DOI:10.1056/nejmoa2405847

Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1

1 finding

Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1

"Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1"

DOI:10.1111/iji.12688

High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2

1 finding

Narcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid.

Show evidence (1 reference)

DOI:10.1111/iji.12688 SUPPORT Human Clinical

Deep research cited this publication as relevant literature for Narcolepsy.

DOI:10.1111/jsr.14277

Narcolepsy and rapid eye movement sleep

1 finding

Since the first description of narcolepsy at the end of the 19th Century, great progress has been made.

"Since the first description of narcolepsy at the end of the 19th Century, great progress has been made."

Show evidence (1 reference)

DOI:10.1111/jsr.14277 SUPPORT Human Clinical

"Since the first description of narcolepsy at the end of the 19th Century, great progress has been made."

Deep research cited this publication as relevant literature for Narcolepsy.

DOI:10.3389/fphar.2024.1415918

Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database

1 finding

Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management.

"Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management."

Show evidence (1 reference)

DOI:10.3389/fphar.2024.1415918 SUPPORT Human Clinical

"Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management."

Deep research cited this publication as relevant literature for Narcolepsy.

DOI:10.3389/fpsyt.2026.1799520

Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine

1 finding

Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy.

"Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy."

Show evidence (1 reference)

DOI:10.3389/fpsyt.2026.1799520 SUPPORT Other

"Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy."

Deep research cited this publication as relevant literature for Narcolepsy.

DOI:10.3390/ctn8030025

Pediatric Narcolepsy Type 1: A State-of-the-Art Review

1 finding

Narcolepsy is a chronic central disorder of hypersomnolence most frequently arising during childhood/adolescence.

"Narcolepsy is a chronic central disorder of hypersomnolence most frequently arising during childhood/adolescence."

Show evidence (1 reference)

DOI:10.3390/ctn8030025 SUPPORT Other

"Narcolepsy is a chronic central disorder of hypersomnolence most frequently arising during childhood/adolescence."

Deep research cited this publication as relevant literature for Narcolepsy.

DOI:10.3390/ijms252211914

The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review

1 finding

Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep.

"Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep."

Show evidence (1 reference)

DOI:10.3390/ijms252211914 SUPPORT Other

"Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep."

Deep research cited this publication as relevant literature for Narcolepsy.

DOI:10.3390/jcm14238444

A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1

1 finding

A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1

"Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder characterized by core clinical manifestations such as excessive daytime sleepiness (EDS), cataplexy, sleep paralysis (SP), hypnagogic and hypnopompic hallucinations (HHs), and disrupted nocturnal sleep (DNS)."

Show evidence (1 reference)

DOI:10.3390/jcm14238444 SUPPORT Other

Deep research cited this publication as relevant literature for Narcolepsy.

Deep Research

Disorder ▸

Disorder

Name: Narcolepsy
Category: Neurological
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 38

Key Pathophysiology Nodes

Orexin/Hypocretin Deficiency
Autoimmune Destruction

Citation Inventory (for evidence mapping)

DOI:10.1001/archneur.59.10.1553
DOI:10.1016/j.sleepx.2024.100122
DOI:10.1038/s41598-024-70594-1
DOI:10.1056/nejmoa2405847
DOI:10.1111/iji.12688
DOI:10.1111/jsr.14277
DOI:10.3389/fphar.2024.1415918
DOI:10.3389/fpsyt.2026.1799520
DOI:10.3390/ctn8030025
DOI:10.3390/ijms252211914
DOI:10.3390/jcm14238444

Falcon ▸

Narcolepsy (Neurological) — Disease Characteristics Research Report

Edison Scientific Literature 47 citations 2026-05-10T06:25:31.387682

Narcolepsy (Neurological) — Disease Characteristics Research Report

Target disease

Narcolepsy is a chronic central disorder of hypersomnolence characterized by excessive daytime sleepiness (EDS) with rapid-eye-movement (REM) sleep dysregulation, and is currently classified into narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). NT1 is strongly linked to orexin/hypocretin deficiency and commonly includes cataplexy; NT2 lacks cataplexy and typically does not show orexin deficiency, with etiology less well established. (biscarini2025narcolepsyandrapid pages 1-2, xu2025acomprehensivereview pages 1-2)

Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

The retrieved full texts did not contain authoritative identifier mappings (ICD-10/ICD-11, MeSH, OMIM, Orphanet, MONDO). Therefore, these identifiers cannot be populated from the current evidence set and should be curated from dedicated terminologies (e.g., ICD/MeSH/MONDO/Orphanet) outside this tool run.

Common synonyms/alternate names

Narcolepsy with cataplexy (historical; largely aligns with NT1) (ariascarrion2026narcolepsyasan pages 3-4)
Narcolepsy without cataplexy (historical; overlaps NT2 and “borderland” phenotypes) (ariascarrion2026narcolepsyasan pages 3-4)
Hypocretin/orexin-deficient narcolepsy (NT1 phenotype emphasis) (xu2025acomprehensivereview pages 1-2, mignot2002theroleof pages 5-6)

Source type note

This report integrates aggregated disease-level resources (reviews, cohorts, pharmacovigilance databases) and some patient-level evidence (e.g., clinical diagnostic criteria tables compiled in reviews). (baldini2024pediatricnarcolepsytype pages 1-2, zhou2024evaluationofpitolisant pages 1-2)

1. Disease information (current understanding)

Narcolepsy is now commonly conceptualized as a disorder of sleep–wake and REM-state boundary control. A modern “systems” view emphasizes multisystem consequences of hypothalamic orexin dysfunction rather than only the classic symptom pentad. (ariascarrion2026narcolepsyasan pages 2-3)

Direct abstract-supported definition/overview: A review of REM sleep and narcolepsy summarizes that narcolepsy is divided into NT1 and NT2, with key criteria relying on SOREMPs captured on polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT), and that NT1 mechanisms are partly elucidated through HLA association and orexin/hypocretin deficiency. (biscarini2025narcolepsyandrapid pages 1-2)

2. Etiology

2.1 Primary causal factors

NT1: orexin neuron loss with strong immune association

NT1 is linked to selective loss/dysfunction of hypothalamic orexin-producing neurons and is increasingly supported as an immune-mediated disease in genetically predisposed individuals. (xu2025acomprehensivereview pages 1-2, ariascarrion2026narcolepsyasan pages 5-6)

A narrative review of T-cell involvement states that NT1 can be understood via interplay of genetic predisposition (notably HLA-DQB1*06:02), environmental triggers (e.g., H1N1 infection/vaccination), and immune mechanisms leading to hypocretin neuronal loss. (xu2024theroleof pages 1-2)

NT2: heterogeneous/less defined

NT2 typically lacks cataplexy and orexin deficiency; its causes remain less well defined. However, subgroups with intermediate orexin levels may overlap immunogenetically with NT1. (biscarini2025narcolepsyandrapid pages 1-2, hamdan2024high‐resolutionhlasequencing pages 1-2, hamdan2024high‐resolutionhlasequencing pages 3-3)

2.2 Risk factors

Genetic risk factors

HLA-DQB1*06:02 / extended haplotypes: In a Swedish cohort, NT1 showed strong association with DRB501:01:01–DRB115:01:01–DQA101:02:01–DQB106:02:01 (OR 7.01, 95% CI 3.97–12.37) and additional genotype combinations reaching OR 23.61 (95% CI 4.48–110.76). (hamdan2024high‐resolutionhlasequencing pages 4-5)
HLA frequency enrichment: A 2024 review notes DQB1*06:02 is present in ~98% of NT1 with cataplexy vs ~25% of the general population, and that homozygosity increases risk vs heterozygosity. (xu2024theroleof pages 2-3)
Non-HLA immune loci: Reported susceptibility loci include TRA (T-cell receptor alpha locus), CTSH, PPAN, P2RY11, IL10RB, and CPT1B, consistent with immune and T-cell biology. (xu2024theroleof pages 3-5, xu2024theroleof pages 2-3)

Environmental/infectious and vaccine-associated risk factors

Influenza A/H1N1 infection and AS03-adjuvanted Pandemrix vaccination (2009–2010) are repeatedly highlighted as environmental triggers linked to increased NT1 incidence in specific settings. (xu2024theroleof pages 1-2, xu2024theroleof pages 3-5, ariascarrion2026narcolepsyasan pages 5-6)

2.3 Protective factors

The retrieved evidence did not provide clearly defined protective genetic variants or modifiable environmental protective factors for narcolepsy in a way that can be summarized with specificity.

2.4 Gene–environment interaction (G×E)

The most consistent G×E framework in the retrieved literature is HLA-driven antigen presentation + environmental priming (H1N1 infection/vaccination) leading to T-cell activation and ultimately selective injury of orexin neurons. (xu2024theroleof pages 1-2, xu2024theroleof pages 7-8, ariascarrion2026narcolepsyasan pages 5-6)

3. Phenotypes (clinical features)

3.1 Core phenotypes (symptoms/signs)

Classic symptom cluster often includes EDS, cataplexy (NT1), disrupted nighttime sleep, sleep paralysis, and hypnagogic/hypnopompic hallucinations. Pediatric NT1 reviews explicitly enumerate these as core symptoms. (baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype pages 2-4)

Pediatric-specific presentation nuances * EDS may be “masked” by hyperactivity/irritability and may be misdiagnosed as ADHD. (baldini2024pediatricnarcolepsytype pages 2-4) * Cataplexy in children may have atypical semiology (“cataplectic facies” with facial hypotonia/ptosis and mixed hyperactive movements). (baldini2024pediatricnarcolepsytype pages 2-4)

3.2 Frequency, onset, progression (where available)

Disturbed nighttime sleep (DNS) frequency in pediatric NT1: 53–78%. (baldini2024pediatricnarcolepsytype pages 2-4)
RBD in young patients with NT1: NT1 reported as leading cause of RBD in young patients (up to 60%). (baldini2024pediatricnarcolepsytype pages 2-4)
Diagnostic/phenotype proportions in a spectrum framing: A review proposes proportions such as “typical cataplexy and all biological markers” 50–80%, with additional borderland groups. (ariascarrion2026narcolepsyasan pages 2-3)

3.3 Quality-of-life impact

A pediatric state-of-the-art review emphasizes that NT1 impairs children’s quality of life and supports early diagnosis and multidisciplinary management, including behavioral and psychosocial interventions. (baldini2024pediatricnarcolepsytype pages 1-2)

3.4 Suggested HPO terms (non-exhaustive, mapping suggestions)

The retrieved sources support the following phenotype constructs; HPO codes should be verified in an ontology browser: * Excessive daytime sleepiness (EDS) (baldini2024pediatricnarcolepsytype pages 2-4) * Cataplexy (baldini2024pediatricnarcolepsytype pages 2-4) * Sleep paralysis (baldini2024pediatricnarcolepsytype pages 1-2) * Hypnagogic/hypnopompic hallucinations (baldini2024pediatricnarcolepsytype pages 1-2) * Fragmented sleep / disturbed nighttime sleep (baldini2024pediatricnarcolepsytype pages 2-4) * REM sleep behavior disorder (baldini2024pediatricnarcolepsytype pages 2-4) * Rapid weight gain/obesity (pediatric onset-associated) (biscarini2025narcolepsyandrapid pages 5-6) * Precocious puberty (pediatric onset-associated) (biscarini2025narcolepsyandrapid pages 5-6)

4. Genetic / molecular information

4.1 Causal genes

For idiopathic NT1, the dominant genetic signal is polygenic (not a single Mendelian “causal gene”). However, a REM-sleep/narcolepsy review notes that a canine model identified mutations in the orexin receptor 2 pathway (historically important to orexin biology). (biscarini2025narcolepsyandrapid pages 1-2)

4.2 Susceptibility loci (selected)

HLA class II region including DQB1*06:02 and extended haplotypes (hamdan2024high‐resolutionhlasequencing pages 4-5, xu2024theroleof pages 2-3)
TRA locus (TCR alpha chain) (xu2024theroleof pages 2-3)
Additional loci reported in a 2024 T-cell narrative review: CTSH rs34593439, PPAN rs1551570, P2RY11 rs2305795, IL10RB rs2834188, CPT1B rs5770917 (xu2024theroleof pages 3-5)

4.3 Biomarkers

CSF hypocretin-1 (orexin-A)

A landmark diagnostic study defined CSF hypocretin-1 ≤110 pg/mL as a best-performing diagnostic cutoff (with >200 pg/mL considered normal), and in “typical cataplexy” reported sensitivity 87% and specificity 99%. (mignot2002theroleof pages 5-6, mignot2002theroleof pages 8-9)

Autoantibodies

A 2024 high-resolution HLA/autoantibody study found no difference in anti-HCRTR2 autoantibody levels across NT1, NT2, idiopathic hypersomnia, and general population controls (p=.8524), suggesting hypocretin receptor 2 is unlikely to be a major autoimmune target in these cohorts. (hamdan2024high‐resolutionhlasequencing pages 1-2, hamdan2024high‐resolutionhlasequencing pages 6-6)

4.4 Epigenetics / omics

The retrieved evidence notes that epigenetic alterations have been reported (e.g., within immune loci), but does not provide specific methylation loci or standardized effect sizes in the excerpts available here. (xu2024theroleof pages 14-15, ariascarrion2026narcolepsyasan pages 7-8)

5. Mechanism / pathophysiology

5.1 Causal chain (NT1; synthesis)

1) Genetic susceptibility: strong HLA class II association (e.g., DQB106:02) and additional immune/TCR loci (xu2024theroleof pages 2-3, hamdan2024high‐resolutionhlasequencing pages 4-5) 2) Environmental priming: H1N1 influenza infection and/or Pandemrix vaccination in specific outbreaks (xu2024theroleof pages 1-2, xu2024theroleof pages 3-5) 3) Immune activation and autoimmunity: evidence supports autoreactive CD4+ and CD8+ T cells targeting orexin-related antigens; molecular mimicry is plausible but not fully resolved across studies (xu2024theroleof pages 7-8, ariascarrion2026narcolepsyasan pages 5-6) 4) Selective orexin neuron loss/dysfunction: substantial neuron loss has been estimated (75–95% loss in NT1 described in a systems review) (ariascarrion2026narcolepsyasan pages 5-6) 5) Network-level consequences*: destabilized wake maintenance and REM boundary control producing EDS, SOREMPs, cataplexy, hallucinations, and sleep paralysis (xu2025acomprehensivereview pages 9-11, biscarini2025narcolepsyandrapid pages 1-2)

5.2 Cell types (CL suggestions) and biological processes (GO suggestions)

Evidence supports immune effector involvement and hypothalamic neuron injury: * CL terms (suggested): CD4-positive T cell; CD8-positive T cell; hypothalamic orexin neuron; histaminergic neuron (TMN) (TAK-861 depolarizes TMN histaminergic neurons via OX2R) (xu2024theroleof pages 7-8, mitsukawa2024tak861apotent pages 2-3) * GO biological processes (suggested): antigen processing and presentation (MHC class II); T cell activation; IFN-γ–mediated signaling and MHC I upregulation; regulation of sleep–wake cycle; regulation of REM sleep (xu2024theroleof pages 7-8, biscarini2025narcolepsyandrapid pages 1-2)

5.3 Anatomical localization (UBERON suggestions)

Lateral hypothalamic area (orexin neuron field) (ariascarrion2026narcolepsyasan pages 3-4)
Hypothalamus (disease framing as hypothalamic encephalopathy) (ariascarrion2026narcolepsyasan pages 2-3)

6. Epidemiology, inheritance, and population

6.1 Prevalence/incidence (selected values present in retrieved sources)

A treatment review describes NT1 prevalence as approximately ~1 in 2000. (xu2025acomprehensivereview pages 1-2)
A systems review summarizes examples of claims/survey-based estimates (not a primary epidemiology study): U.S. prevalence 37.7/100,000 and incidence 2.6/100,000 person-years; Japan claims prevalence ~37.5/100,000 and incidence 5.1/100,000 person-years, with substantial geographic variation and diagnostic uncertainty (notably for NT2). (ariascarrion2026narcolepsyasan pages 3-4)

6.2 Inheritance pattern

The evidence supports narcolepsy (especially NT1) as multifactorial/polygenic with strong HLA association rather than Mendelian inheritance. (xu2024theroleof pages 2-3, xu2024theroleof pages 3-5)

6.3 Demographics and heterogeneity

Pediatric narcolepsy is emphasized as frequently beginning in childhood/adolescence, and pediatric phenotype has distinctive features (e.g., weight gain and atypical cataplexy semiology). (biscarini2025narcolepsyandrapid pages 5-6, baldini2024pediatricnarcolepsytype pages 2-4)

7. Diagnostics

7.1 Standard diagnostic criteria (ICSD-3-TR, 2023)

The pediatric NT1 review reproduces ICSD-3-TR (2023) diagnostic criteria for NT1 and NT2, including EDS duration, MSLT requirements (mean sleep latency ≤8 min and ≥2 SOREMPs), cataplexy status, and CSF hypocretin thresholds, and illustrates the ICSD-3-TR change that allows nocturnal PSG SOREMP + cataplexy to suffice for NT1 diagnosis even if MSLT is not definitive. (baldini2024pediatricnarcolepsytype media 3ad4bd72, baldini2024pediatricnarcolepsytype pages 8-9)

7.2 Core tests

Overnight PSG + MSLT remain key objective tests, anchored on SOREMP detection. (biscarini2025narcolepsyandrapid pages 1-2)
CSF hypocretin-1 is described as the strongest biomarker in reviews and has robust test characteristics in foundational work. (ariascarrion2026narcolepsyasan pages 21-22, mignot2002theroleof pages 5-6)

7.3 Test performance and pediatric considerations

Nocturnal SOREMP in pediatrics: reported specificity 97.3% and sensitivity 54.8% (reviewed pediatric data). (baldini2024pediatricnarcolepsytype pages 8-9)
CSF hypocretin: ≤110 pg/mL cutoff with high specificity and good sensitivity for typical cataplexy. (mignot2002theroleof pages 5-6, mignot2002theroleof pages 8-9)

7.4 Differential diagnosis highlights (from pediatric review excerpts)

Diagnostic workup emphasizes excluding insufficient sleep and circadian disorders (actigraphy 7–10 days), and distinguishing NT2 from idiopathic hypersomnia (IH) via SOREMP patterns and/or total sleep time. (baldini2024pediatricnarcolepsytype pages 9-11)

8. Treatment (current applications and real-world implementation)

8.1 Symptomatic pharmacotherapy (current standard)

A synthesis review rates modafinil/armodafinil, solriamfetol, pitolisant, and sodium oxybate formulations as high-certainty, strong-recommendation symptomatic treatments. (ariascarrion2026narcolepsyasan pages 21-22)

Pediatric regulatory status and practice A pediatric NT1 review notes: * No approvals under age 6. * Sodium oxybate is approved by FDA and EMA for ages ≥7. * EMA approved pitolisant in 2023 for patients >6 years with or without cataplexy. (baldini2024pediatricnarcolepsytype pages 11-13)

8.2 Oxybate dosing innovations (real-world implementation)

RESTORE (2024) evaluated switching from twice-nightly immediate-release oxybate to once-nightly extended-release sodium oxybate: * 93.9% (92/98) preferred once-nightly dosing. * Prior to switching, 69.2% had missed the second dose at least once; nocturnal mobility after the second dose was common, with reported falls and injuries. * After switching, 91.2% felt better able to follow the recommended dosing schedule. These data emphasize adherence/safety burdens of middle-of-the-night redosing and a real-world rationale for simplified regimens. (roy2024restoreoncenightlyoxybate pages 1-2, roy2024restoreoncenightlyoxybate pages 2-3)

8.3 Mechanism-based “orexin restoration” therapeutics (recent developments)

A major 2023–2024 development area is small-molecule OX2R agonists designed to replace deficient orexin signaling.

Preclinical evidence (2024): TAK-861 (oveporexton) A 2024 Scientific Reports study characterized TAK-861 as an oral OX2R-selective agonist with OX2R EC50 2.5 nM and ~3,000-fold selectivity over OX1R. It promoted wakefulness in mice and monkeys (minimum effective dose 1 mg/kg) and improved narcolepsy-like phenotypes in NT1 mouse models (orexin/ataxin-3 and orexin-tTA;TetO DTA), including reduced wake fragmentation and reduced cataplexy-like episodes. (mitsukawa2024tak861apotent pages 1-2, mitsukawa2024tak861apotent pages 3-4, mitsukawa2024tak861apotent pages 2-3, mitsukawa2024tak861apotent pages 10-11)

Clinical development (trial registry; real-world implementation horizon) Multiple trials are registered for orexin agonists including TAK-861 and danavorexton (TAK-925). Examples include completed and recruiting studies spanning Phase 1–3 (e.g., NCT05687903 Phase 2; Phase 3 trials listed for TAK-861; TAK-925 Phase 1 programs). (xu2025acomprehensivereview pages 9-11)

8.4 Safety signals and pharmacovigilance (recent data)

A 2024 FAERS analysis (2019–2023) identified signal counts: 50 signals/762 cases for pitolisant, 640/46,962 for sodium oxybate, 40/1,228 for solriamfetol, and 72/632 for modafinil. Psychiatric and nervous system disorders predominated; sodium oxybate showed strong respiratory-related signals (e.g., sleep apnea syndrome n=1326 with high disproportionality metrics) and hypertension signals. These are signal-detection outputs without denominators and cannot be interpreted as incidence rates, but they inform monitoring priorities. (zhou2024evaluationofpitolisant pages 1-2, zhou2024evaluationofpitolisant pages 8-9)

8.5 Suggested MAXO terms (treatment action ontology; mapping suggestions)

Based on interventions discussed: * Pharmacotherapy for hypersomnolence / wake promotion (modafinil/armodafinil/solriamfetol/pitolisant) (ariascarrion2026narcolepsyasan pages 21-22) * Oxybate therapy (sodium oxybate; low-sodium oxybate; once-nightly formulations) (roy2024restoreoncenightlyoxybate pages 1-2, baldini2024pediatricnarcolepsytype pages 11-13) * Orexin receptor agonist therapy (OX2R agonists) (mitsukawa2024tak861apotent pages 1-2) * Behavioral sleep intervention (planned naps, sleep hygiene, school programs) (baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype pages 11-13)

9. Prevention

9.1 Primary prevention

No established primary prevention strategy exists for idiopathic NT1/NT2.

9.2 Secondary/tertiary prevention (complication reduction)

Evidence supports early diagnosis and multidisciplinary management in pediatrics to reduce educational/psychosocial impact, plus careful monitoring for comorbidities (metabolic/endocrine, psychiatric) and medication adverse effects. (baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype pages 14-15)

9.3 Vaccine-related considerations

Pandemrix-associated risk signals are part of the etiologic history in some countries, but causality and generalization to modern vaccines are complex; a recent immunology-focused narrative emphasizes that mechanistic mimicry is plausible but incompletely resolved and that findings vary across studies. (xu2024theroleof pages 7-8, ariascarrion2026narcolepsyasan pages 5-6)

10. Other species / natural disease and model organisms

10.1 Model organisms used in current research

The orexin system has strong translational animal models. A 2024 preclinical therapeutic paper uses: * orexin/ataxin-3 mice (orexin neuron degeneration model) * orexin-tTA;TetO DTA mice (conditional orexin neuron ablation) These models support evaluation of orexin-pathway therapeutics for wake consolidation and cataplexy-like behaviors. (mitsukawa2024tak861apotent pages 1-2, mitsukawa2024tak861apotent pages 10-11)

10.2 Model limitations

The retrieved evidence emphasizes that models typically capture fragments of the human phenotype (e.g., cataplexy-like episodes, fragmentation) and are most directly aligned with NT1 biology rather than NT2 heterogeneity. (mitsukawa2024tak861apotent pages 1-2, biscarini2025narcolepsyandrapid pages 1-2)

11. Key recent evidence summary table

The following table consolidates the most actionable recent and foundational evidence captured in this tool run.

Topic	Key data/statistics	Source (first author, year, journal)	URL	Notes
ICSD-3-TR diagnostic criteria	2023 ICSD-3-TR allows NT1 diagnosis when cataplexy is present together with a nocturnal PSG SOREMP, even without relying on MSLT/hypocretin confirmation; standard criteria still include mean sleep latency ≤8 min and ≥2 SOREMPs, or CSF hypocretin-1 ≤110 pg/mL / <1/3 of controls (baldini2024pediatricnarcolepsytype pages 8-9, baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype media 3ad4bd72)	Baldini, 2024, Clinical and Translational Neuroscience	https://doi.org/10.3390/ctn8030025	Useful update for diagnostic workflows, especially pediatrics and difficult MSLT cases
Pediatric phenotypes	Disturbed nighttime sleep (DNS) affects 53–78% of pediatric NT1; REM sleep behavior disorder (RBD) is reported in up to 60% and may be early/severe in children (baldini2024pediatricnarcolepsytype pages 2-4)	Baldini, 2024, Clinical and Translational Neuroscience	https://doi.org/10.3390/ctn8030025	Pediatric presentation can include atypical cataplexy and ADHD-like behaviors
CSF hypocretin biomarker	CSF hypocretin-1 cutoff ≤110 pg/mL (with >200 pg/mL considered normal); in typical cataplexy, sensitivity 87% and specificity 99%, PPV 96%, NPV 96% (mignot2002theroleof pages 5-6, mignot2002theroleof pages 8-9)	Mignot, 2002, Archives of Neurology	https://doi.org/10.1001/archneur.59.10.1553	Strongest biomarker for NT1; interpretation needed in secondary hypothalamic disease
HLA associations	NT1-associated haplotype DRB501:01:01-DRB115:01:01-DQA101:02:01-DQB106:02:01: OR 7.01 (95% CI 3.97–12.37); genotype OR 9.15. Multilocus genotype including DRB401:03:01/DRB104:01:01/DQA103:02 or 03:03:01/DQB1*03:01:01: OR 23.61 (95% CI 4.48–110.76). Anti-HCRTR2 autoantibodies were not different across groups (p=.8524) (hamdan2024high‐resolutionhlasequencing pages 4-5, hamdan2024high‐resolutionhlasequencing pages 1-2, hamdan2024high‐resolutionhlasequencing pages 6-6)	Hamdan, 2024, International Journal of Immunogenetics	https://doi.org/10.1111/iji.12688	Supports strong HLA-driven susceptibility; no support here for HCRTR2 autoantibody pathogenicity
T-cell autoimmunity and risk loci	NT1 is framed as predominantly T-cell–mediated autoimmunity; HLA-DQB1*06:02 present in ~98% of NT1 with cataplexy vs ~25% of general population; reported risk loci include TRA, CTSH rs34593439, PPAN rs1551570, P2RY11 rs2305795, IL10RB/rs2834188, CPT1B rs5770917; H1N1/Pandemrix implicated as environmental triggers (xu2024theroleof pages 2-3, xu2024theroleof pages 3-5, xu2024theroleof pages 7-8, xu2024theroleof pages 1-2)	Xu, 2024, International Journal of Molecular Sciences	https://doi.org/10.3390/ijms252211914	Molecular mimicry is plausible but incompletely resolved
TAK-861 preclinical evidence	TAK-861 (oveporexton) activated OX2R with EC50 2.5 nM and ~3,000-fold selectivity over OX1R; improved wakefulness and reduced cataplexy-like episodes in orexin/ataxin-3 and orexin-tTA;TetO DTA mouse models; wake-promoting MED 1 mg/kg in mice and monkeys (mitsukawa2024tak861apotent pages 1-2, mitsukawa2024tak861apotent pages 3-4, mitsukawa2024tak861apotent pages 2-3, mitsukawa2024tak861apotent pages 10-11)	Mitsukawa, 2024, Scientific Reports	https://doi.org/10.1038/s41598-024-70594-1	Mechanism-based therapy aimed at replacing lost orexin signaling
Oveporexton phase 2 outcomes	In NT1, 8-week trial: mean MWT change +12.5 to +25.4 min vs -1.2 placebo; ESS change -8.9 to -13.8 vs -2.5 placebo; weekly cataplexy at week 8: 2.48–5.89 vs 8.76 placebo depending on dose; common AEs insomnia 48%, urinary urgency 33%, urinary frequency 32%; no hepatotoxicity reported (abstract evidence from retrieved paper search)	Dauvilliers, 2025, New England Journal of Medicine	https://doi.org/10.1056/NEJMoa2405847	Phase 2 TAK-861/oveporexton trial, NCT05687903
Once-nightly oxybate preference	In RESTORE, 92/98 (93.9%) preferred once-nightly sodium oxybate after switching; 69.2% had missed the second IR oxybate dose at least once; 91.2% felt better able to follow dosing schedule; 92.6% would recommend ON-SXB (roy2024restoreoncenightlyoxybate pages 1-2, roy2024restoreoncenightlyoxybate pages 2-3, roy2024restoreoncenightlyoxybate pages 4-5)	Roy, 2024, Sleep Medicine: X	https://doi.org/10.1016/j.sleepx.2024.100122	Highlights real-world burden of middle-of-the-night redosing
Real-world pharmacovigilance	FAERS 2019–2023 identified 50 signals/762 cases for pitolisant, 640/46,962 for sodium oxybate, 40/1,228 for solriamfetol, and 72/632 for modafinil; psychiatric and nervous system ADEs predominated. Sodium oxybate had notable signals for sleep apnea syndrome (n=1326), respiratory depression (n=104), apnea (n=95), and hypertension (n=1081) (zhou2024evaluationofpitolisant pages 1-2, zhou2024evaluationofpitolisant pages 3-4, zhou2024evaluationofpitolisant pages 8-9)	Zhou, 2024, Frontiers in Pharmacology	https://doi.org/10.3389/fphar.2024.1415918	FAERS signals are hypothesis-generating, not incidence estimates
Epidemiology snapshot	Recent review summarized prevalence around 37.7/100,000 in the U.S. and incidence ~2.6/100,000 person-years; Japan claims data ~37.5/100,000 prevalence and 5.1/100,000 person-years incidence, with strong geographic variability (ariascarrion2026narcolepsyasan pages 3-4)	Arias-Carrión, 2026, Frontiers in Psychiatry	https://doi.org/10.3389/fpsyt.2026.1799520	Useful contextual benchmark; not a primary epidemiology study

Table: This table compiles high-yield recent and foundational evidence for narcolepsy across diagnosis, biomarkers, immunogenetics, therapeutics, and real-world safety. It is useful as a quick-reference summary for a disease knowledge base entry.

12. Notes on evidence gaps and curation requirements

Disease identifiers (ICD/MeSH/MONDO/OMIM/Orphanet): not present in the retrieved literature excerpts; must be curated separately.
NT2 biology and biomarkers: evidence in this run supports heterogeneity and possible overlap subgroups (intermediate orexin), but a definitive mechanism is not established here. (hamdan2024high‐resolutionhlasequencing pages 3-3, hamdan2024high‐resolutionhlasequencing pages 1-2)
Autoantibodies: HCRTR2 autoantibodies were not supported as disease-specific in the 2024 cohort study. (hamdan2024high‐resolutionhlasequencing pages 6-6)

References (URLs and publication dates)

Primary sources used (examples; see citations inline): * Baldini V. et al. Pediatric Narcolepsy Type 1: A State-of-the-Art Review. Clinical and Translational Neuroscience. 2024-06. https://doi.org/10.3390/ctn8030025 (baldini2024pediatricnarcolepsytype pages 1-2) * Xu W. et al. The Role of T Cells in the Pathogenesis of Narcolepsy Type 1. Int J Mol Sci. 2024-11. https://doi.org/10.3390/ijms252211914 (xu2024theroleof pages 1-2) * Hamdan S. et al. High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies. Int J Immunogenet. 2024-06. https://doi.org/10.1111/iji.12688 (hamdan2024high‐resolutionhlasequencing pages 1-2) * Mitsukawa K. et al. TAK-861 OX2R agonist preclinical study. Scientific Reports. 2024-09. https://doi.org/10.1038/s41598-024-70594-1 (mitsukawa2024tak861apotent pages 1-2) * Roy A. et al. RESTORE once-nightly oxybate preference. Sleep Medicine: X. 2024-12. https://doi.org/10.1016/j.sleepx.2024.100122 (roy2024restoreoncenightlyoxybate pages 1-2) * Zhou X. et al. FAERS pharmacovigilance analysis. Front Pharmacol. 2024-11. https://doi.org/10.3389/fphar.2024.1415918 (zhou2024evaluationofpitolisant pages 1-2) * Mignot E. et al. CSF hypocretin measurement diagnostic performance. Archives of Neurology. 2002-10. https://doi.org/10.1001/archneur.59.10.1553 (mignot2002theroleof pages 5-6)

References

(biscarini2025narcolepsyandrapid pages 1-2): Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, and Yves Dauvilliers. Narcolepsy and rapid eye movement sleep. Journal of Sleep Research, Jul 2025. URL: https://doi.org/10.1111/jsr.14277, doi:10.1111/jsr.14277. This article has 14 citations and is from a peer-reviewed journal.
(xu2025acomprehensivereview pages 1-2): Qinglin Xu, Yigang Chen, Tiantian Wang, Qiongbin Zhu, Jiahui Xu, and Lisan Zhang. A comprehensive review of current and emerging treatments for narcolepsy type 1. Journal of Clinical Medicine, 14:8444, Nov 2025. URL: https://doi.org/10.3390/jcm14238444, doi:10.3390/jcm14238444. This article has 1 citations.
(ariascarrion2026narcolepsyasan pages 3-4): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(mignot2002theroleof pages 5-6): Emmanuel Mignot, Gert Jan Lammers, Beth Ripley, Michele Okun, Sonia Nevsimalova, Sebastiaan Overeem, Jitka Vankova, Jed Black, John Harsh, Claudio Bassetti, Harald Schrader, and Seiji Nishino. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Archives of neurology, 59 10:1553-62, Oct 2002. URL: https://doi.org/10.1001/archneur.59.10.1553, doi:10.1001/archneur.59.10.1553. This article has 1400 citations.
(baldini2024pediatricnarcolepsytype pages 1-2): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(zhou2024evaluationofpitolisant pages 1-2): Xiaodan Zhou, Jia Chen, Bangtian Xu, and Li Chen. Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the faers database. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1415918, doi:10.3389/fphar.2024.1415918. This article has 4 citations.
(ariascarrion2026narcolepsyasan pages 2-3): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(ariascarrion2026narcolepsyasan pages 5-6): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(xu2024theroleof pages 1-2): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(hamdan2024high‐resolutionhlasequencing pages 1-2): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.
(hamdan2024high‐resolutionhlasequencing pages 3-3): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.
(hamdan2024high‐resolutionhlasequencing pages 4-5): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.
(xu2024theroleof pages 2-3): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(xu2024theroleof pages 3-5): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(xu2024theroleof pages 7-8): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(baldini2024pediatricnarcolepsytype pages 2-4): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(biscarini2025narcolepsyandrapid pages 5-6): Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, and Yves Dauvilliers. Narcolepsy and rapid eye movement sleep. Journal of Sleep Research, Jul 2025. URL: https://doi.org/10.1111/jsr.14277, doi:10.1111/jsr.14277. This article has 14 citations and is from a peer-reviewed journal.
(mignot2002theroleof pages 8-9): Emmanuel Mignot, Gert Jan Lammers, Beth Ripley, Michele Okun, Sonia Nevsimalova, Sebastiaan Overeem, Jitka Vankova, Jed Black, John Harsh, Claudio Bassetti, Harald Schrader, and Seiji Nishino. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Archives of neurology, 59 10:1553-62, Oct 2002. URL: https://doi.org/10.1001/archneur.59.10.1553, doi:10.1001/archneur.59.10.1553. This article has 1400 citations.
(hamdan2024high‐resolutionhlasequencing pages 6-6): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.
(xu2024theroleof pages 14-15): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(ariascarrion2026narcolepsyasan pages 7-8): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(xu2025acomprehensivereview pages 9-11): Qinglin Xu, Yigang Chen, Tiantian Wang, Qiongbin Zhu, Jiahui Xu, and Lisan Zhang. A comprehensive review of current and emerging treatments for narcolepsy type 1. Journal of Clinical Medicine, 14:8444, Nov 2025. URL: https://doi.org/10.3390/jcm14238444, doi:10.3390/jcm14238444. This article has 1 citations.
(mitsukawa2024tak861apotent pages 2-3): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.
(baldini2024pediatricnarcolepsytype media 3ad4bd72): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(baldini2024pediatricnarcolepsytype pages 8-9): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(ariascarrion2026narcolepsyasan pages 21-22): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(baldini2024pediatricnarcolepsytype pages 9-11): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(baldini2024pediatricnarcolepsytype pages 11-13): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(roy2024restoreoncenightlyoxybate pages 1-2): Asim Roy, Thomas Stern, John Harsh, J. Douglas Hudson, Akinyemi O. Ajayi, Bruce C. Corser, Emmanuel Mignot, Adrian Santamaria, Anne Marie Morse, Brian Abaluck, Sally Ibrahim, Paula K. Schweitzer, Katie Lancaster, Jordan Dubow, and Jennifer Gudeman. Restore: once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. Sleep Medicine: X, 8:100122, Dec 2024. URL: https://doi.org/10.1016/j.sleepx.2024.100122, doi:10.1016/j.sleepx.2024.100122. This article has 9 citations.
(roy2024restoreoncenightlyoxybate pages 2-3): Asim Roy, Thomas Stern, John Harsh, J. Douglas Hudson, Akinyemi O. Ajayi, Bruce C. Corser, Emmanuel Mignot, Adrian Santamaria, Anne Marie Morse, Brian Abaluck, Sally Ibrahim, Paula K. Schweitzer, Katie Lancaster, Jordan Dubow, and Jennifer Gudeman. Restore: once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. Sleep Medicine: X, 8:100122, Dec 2024. URL: https://doi.org/10.1016/j.sleepx.2024.100122, doi:10.1016/j.sleepx.2024.100122. This article has 9 citations.
(mitsukawa2024tak861apotent pages 1-2): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.
(mitsukawa2024tak861apotent pages 3-4): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.
(mitsukawa2024tak861apotent pages 10-11): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.
(zhou2024evaluationofpitolisant pages 8-9): Xiaodan Zhou, Jia Chen, Bangtian Xu, and Li Chen. Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the faers database. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1415918, doi:10.3389/fphar.2024.1415918. This article has 4 citations.
(baldini2024pediatricnarcolepsytype pages 14-15): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(roy2024restoreoncenightlyoxybate pages 4-5): Asim Roy, Thomas Stern, John Harsh, J. Douglas Hudson, Akinyemi O. Ajayi, Bruce C. Corser, Emmanuel Mignot, Adrian Santamaria, Anne Marie Morse, Brian Abaluck, Sally Ibrahim, Paula K. Schweitzer, Katie Lancaster, Jordan Dubow, and Jennifer Gudeman. Restore: once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. Sleep Medicine: X, 8:100122, Dec 2024. URL: https://doi.org/10.1016/j.sleepx.2024.100122, doi:10.1016/j.sleepx.2024.100122. This article has 9 citations.
(zhou2024evaluationofpitolisant pages 3-4): Xiaodan Zhou, Jia Chen, Bangtian Xu, and Li Chen. Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the faers database. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1415918, doi:10.3389/fphar.2024.1415918. This article has 4 citations.

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Pathophysiology

Phenotypes

Genetic Associations

Treatments

Environmental Factors

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)

Narcolepsy (Neurological) — Disease Characteristics Research Report

Target disease

Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

Common synonyms/alternate names

Source type note

1. Disease information (current understanding)

2. Etiology

2.1 Primary causal factors

NT1: orexin neuron loss with strong immune association

NT2: heterogeneous/less defined

2.2 Risk factors

Genetic risk factors

Environmental/infectious and vaccine-associated risk factors

2.3 Protective factors

2.4 Gene–environment interaction (G×E)

3. Phenotypes (clinical features)

3.1 Core phenotypes (symptoms/signs)

3.2 Frequency, onset, progression (where available)

3.3 Quality-of-life impact

3.4 Suggested HPO terms (non-exhaustive, mapping suggestions)

4. Genetic / molecular information

4.1 Causal genes

4.2 Susceptibility loci (selected)

4.3 Biomarkers

CSF hypocretin-1 (orexin-A)

Autoantibodies

4.4 Epigenetics / omics

5. Mechanism / pathophysiology

5.1 Causal chain (NT1; synthesis)

5.2 Cell types (CL suggestions) and biological processes (GO suggestions)

5.3 Anatomical localization (UBERON suggestions)

6. Epidemiology, inheritance, and population

6.1 Prevalence/incidence (selected values present in retrieved sources)

6.2 Inheritance pattern

6.3 Demographics and heterogeneity

7. Diagnostics

7.1 Standard diagnostic criteria (ICSD-3-TR, 2023)

7.2 Core tests

7.3 Test performance and pediatric considerations

7.4 Differential diagnosis highlights (from pediatric review excerpts)

8. Treatment (current applications and real-world implementation)

8.1 Symptomatic pharmacotherapy (current standard)

8.2 Oxybate dosing innovations (real-world implementation)

8.3 Mechanism-based “orexin restoration” therapeutics (recent developments)

8.4 Safety signals and pharmacovigilance (recent data)

8.5 Suggested MAXO terms (treatment action ontology; mapping suggestions)

9. Prevention

9.1 Primary prevention

9.2 Secondary/tertiary prevention (complication reduction)

9.3 Vaccine-related considerations

10. Other species / natural disease and model organisms

10.1 Model organisms used in current research

10.2 Model limitations

11. Key recent evidence summary table

12. Notes on evidence gaps and curation requirements

References (URLs and publication dates)